Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Cinzia Maugeri"'
Autor:
Andrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, Luca Lo Nigro, Elisa Mauro, Calogero Vetro, Marina Parisi, Cinzia Maugeri, Paolo Fabio Fiumara, Giuseppe Milone, Alessandra Romano, Francesco Di Raimondo, Salvatore Leotta
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Blinatumomab is a bispecific anti-CD3 and anti-CD19 antibody that acts as a T-cell engager: by binding CD19+ lymphoblasts, blinatumomab recruits cytotoxic CD3+ T-lymphocytes to target the cancer cells. Here we describe seven different patients affect
Externí odkaz:
https://doaj.org/article/6d1ea67282854a9192f0384a596efbcd
Autor:
Andrea Duminuco, Antonella Nardo, Alessandra Orofino, Alessandra Romano, Amalia Stefania Figuera, Annalisa Chiarenza, Uros Markovic, Laura Caruso, Giuliana Giunta, Salvatore Leotta, Giuseppe Milone, Alessandra Cupri, Concetta Conticello, Vittorio Del Fabro, Elisa Mauro, Cinzia Maugeri, Calogero Vetro, Marina Parisi, Francesco DI Raimondo, Giuseppe Palumbo
Publikováno v:
HemaSphere, Vol 7, p e4986333 (2023)
Externí odkaz:
https://doaj.org/article/d68e541d16fd4c7a9d6233c6a640b80e
Autor:
Manlio Fazio, Calogero Vetro, Uroš Markovic, Andrea Duminuco, Marina Parisi, Cinzia Maugeri, Elisa Mauro, Nunziatina Laura Parrinello, Fabio Stagno, Loredana Villari, Anna Maria Triolo, Stefania Stella, Giuseppe A. Palumbo, Francesco Di Raimondo, Alessandra Romano, Roberta Zanotti
Publikováno v:
Clinical Case Reports, Vol 11, Iss 7, Pp n/a-n/a (2023)
Abstract Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine–venetoclax–midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic s
Externí odkaz:
https://doaj.org/article/ad426aa945fb49c6a3745848a1c8e251
Autor:
Andrea Duminuco, Calogero Vetro, Cinzia Maugeri, Elisa Mauro, Giuseppe A. M. Palumbo, Marina S. Parisi, Benedetta Esposito, Giuseppe Giuliano, Alessandra Romano, Francesco Di Raimondo
Publikováno v:
Hematology Reports, Vol 14, Iss 2, Pp 67-72 (2022)
Infections occurring in immunocompromised patients after intensive chemotherapy are often difficult to eradicate and are capable of even being fatal. New emergent and dangerous drug-resistant micro-organisms are likely to appear in these specific sce
Externí odkaz:
https://doaj.org/article/027f064dd3984f54bdc66fad67e82149
Autor:
Andrea Duminuco, Francesco Di Raimondo, Elisa Mauro, Cinzia Maugeri, Marina Silvia Parisi, Giuseppe A.M. Palumbo, Paolo F. Fiumara, Bruno Garibaldi, Calogero Vetro
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 7, Iss , Pp 100184- (2022)
Acute myeloid leukemia is a hematological disease with a poor prognosis. Blast cells that characterize the disease are generally present in the bone marrow, but they can sometimes be located in different organs. This rare event can occur at diagnosis
Externí odkaz:
https://doaj.org/article/c926eea2a2e54dff8c356a8562a86a2a
Autor:
Andrea Duminuco, Giuseppe A. M. Palumbo, Bruno Garibaldi, Rosario Foti, Francesco Di Raimondo, Cinzia Maugeri, Elisa Mauro, Paolo F. Fiumara, Calogero Vetro
Publikováno v:
Hemato, Vol 2, Iss 2, Pp 347-352 (2021)
We report a case of a young patient suffering from very-high risk B-acute lymphoblastic leukemia (ALL) refractory to first-line therapy with early central nervous system relapse, sequentially treated with inotuzumab. At this timepoint, the patient sh
Externí odkaz:
https://doaj.org/article/5d8ca7c1db22479ea5ca147760bc3dc5
Autor:
Lucia Gozzo, Antonella Nardo, Serena Brancati, Antongiulio Judica, Andrea Duminuco, Cinzia Maugeri, Marina Parisi, Laura Longo, Daniela Cristina Vitale, Rosy Ruscica, Giovanni Luca Romano, Elisa Mauro, Paolo Fabio Fiumara, Giuseppe Alberto Maria Palumbo, Francesco Di Raimondo, Calogero Vetro, Filippo Drago
Publikováno v:
Healthcare, Vol 11, Iss 10, p 1479 (2023)
Gilteritinib has been approved as monotherapy in adults with acute myeloid leukemia (AML) FLT3 mutated with relapsed or refractory disease, in light of its advantages in terms of survival and the favorable safety profile. Hepatobiliary disorders and
Externí odkaz:
https://doaj.org/article/00478b690bba4ee1b674d5b62eb87424
Autor:
Lucia Gozzo, Calogero Vetro, Serena Brancati, Laura Longo, Daniela Cristina Vitale, Giovanni Luca Romano, Elisa Mauro, Paolo Fabio Fiumara, Cinzia Maugeri, Marina Silvia Parisi, Ilaria Dulcamare, Bruno Garibaldi, Andrea Duminuco, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Filippo Drago
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
The potent oral inhibitor of BCL2, venetoclax (VEN), used to treat adults with chronic lymphocytic leukaemia, has been approved in US for the treatment of naïve patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy and recently
Externí odkaz:
https://doaj.org/article/2ff780c252104344b836dc38e573699f
Autor:
Andrea Duminuco, Elisa Mauro, Giuseppe A. M. Palumbo, Bruno Garibaldi, Marina Parisi, Francesco Di Raimondo, Cinzia Maugeri, Calogero Vetro
Publikováno v:
Hematology Reports, Vol 13, Iss 4 (2021)
Fungal infections occurring in immunocompromised patients after immuno-chemotherapy treatment, are often difficult to eradicate and capable of even being fatal. Systemic mycoses affecting severely immunocompromised patients often manifest acutely wit
Externí odkaz:
https://doaj.org/article/a2c92240702f4e08a388d4bac8cdc68f
Autor:
Uros Markovic, Alessandra Romano, Vittorio Del Fabro, Claudia Bellofiore, Anna Bulla, Marina Silvia Parisi, Salvatore Leotta, Massimo Gentile, Clotilde Cangialosi, Iolanda Vincelli, Giuseppe Mineo, Marco Rossi, Massimo Poidomani, Giuseppina Uccello, Cinzia Maugeri, Donato Mannina, Vanessa Innao, Francesco Di Raimondo, Concetta Conticello
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who received at least three prior lines of therapy, including proteasome inhibitor an
Externí odkaz:
https://doaj.org/article/62d114c5feae4199a24298a5f48db9e5